Convalescent plasma (CP) therapy is rapidly becoming an established consideration in the treatment of COVID-19 patients though there is a need to critically review this area for proof of efficacy. Neutralizing antibodies (NAb) present in CP generated in response to SARS-CoV-2 infection directed against the receptor-binding domain (RBD) of the spike protein are considered to play main role in viral clearance. CP infusion may also help in the modulation of immune response by its immunomodulatory effect. The FDA allows for administration of CP to COVID-19 patients. The present published literature in COVID-19 is limited to case series and randomised controlled trial where plasma therapy was used in moderate, severe and critically ill patients. Though multiple uncertainties exist regarding to its efficacy, appropriate donor selection and NAb titres, the efficacy data of CP use inCOVID-19 is limited having shown hope with early and severe to critically ill COVID-19 patients.

恢复期血浆 (CP) 疗法正迅速成为治疗 COVID-19 患者的既定考虑因素，尽管需要对该领域进行严格审查以证明疗效。CP 中存在的针对 SARS-CoV-2 感染而产生的针对刺突蛋白受体结合域 (RBD) 的中和抗体 (NAb) 被认为在病毒清除中起主要作用。CP 输注也可能通过其免疫调节作用帮助调节免疫反应。FDA 允许对 COVID-19 患者使用 CP。目前在 COVID-19 中发表的文献仅限于病例系列和随机对照试验，其中血浆疗法用于中度、重度和危重患者。尽管关于其疗效、适当的供体选择和 NAb 滴度存在多种不确定性，